Infectious Risk and Variability of Hemoglobin Level in Patients Undergoing Hemodialysis.

ABSTRACT:

Introduction

In the management of anemia in chronic kidney disease, hemoglobin levels often fall below or exceed target ranges. Past retrospective cohort studies of patients undergoing hemodialysis with conventional erythropoiesis stimulating agents (ESAs) found that hemoglobin level fluctuations predicted mortality and cardiovascular adverse events; long-acting agents were thereafter widely available. An updated validation by a prospective cohort study was needed.

Methods

Using Cox regression models, we evaluated associations between hemoglobin variability and all-cause death, hospitalization, and cardiovascular, thrombotic, or infectious adverse event outcomes in 3063 hemodialysis patients' data from the Japanese Dialysis Outcomes and Practice Patterns Study (J-DOPPS) from

SUBMITTER: Nishi H 

PROVIDER: S-EPMC10496019 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature